FY2027 Earnings Forecast for Aravive, Inc. Issued By HC Wainwright (NASDAQ:ARAV)

Aravive, Inc. (NASDAQ:ARAV – Get Rating) – Research analysts at HC Wainwright upped their FY2027 earnings per share (EPS) estimates for shares of Aravive in a report released on Wednesday, March 15th. HC Wainwright analyst J. Pantginis now expects that the company will post earnings of $0.78 per share for the year, up from their previous estimate of $0.64. HC Wainwright has a “Buy” rating and a $12.00 price objective on the stock. The consensus estimate for Aravive’s current full-year earnings is ($1.38) per share.

Separately, EF Hutton Acquisition Co. I reiterated a “buy” rating and set a $10.00 target price on shares of Aravive in a research report on Tuesday, February 14th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $9.20.

Aravive Trading Up 7.1 %

NASDAQ ARAV opened at $1.96 on Friday. The business’s 50 day moving average is $1.84 and its two-hundred day moving average is $1.41. Aravive has a 12-month low of $0.58 and a 12-month high of $2.23. The stock has a market capitalization of $117.27 million, a price-to-earnings ratio of -0.83 and a beta of 2.35.

Institutional Investors Weigh In On Aravive

Institutional investors have recently modified their holdings of the company. Renaissance Technologies LLC boosted its stake in shares of Aravive by 35.0% during the 2nd quarter. Renaissance Technologies LLC now owns 374,945 shares of the company’s stock worth $370,000 after acquiring an additional 97,116 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Aravive by 4.6% during the 4th quarter. Geode Capital Management LLC now owns 142,787 shares of the company’s stock worth $188,000 after acquiring an additional 6,238 shares in the last quarter. Two Sigma Investments LP purchased a new stake in shares of Aravive during the 4th quarter worth approximately $167,000. Millennium Management LLC lifted its stake in Aravive by 58.9% in the 2nd quarter. Millennium Management LLC now owns 96,838 shares of the company’s stock valued at $96,000 after buying an additional 35,900 shares in the last quarter. Finally, Jane Street Group LLC lifted its stake in Aravive by 271.9% in the 4th quarter. Jane Street Group LLC now owns 42,115 shares of the company’s stock valued at $56,000 after buying an additional 30,792 shares in the last quarter. Hedge funds and other institutional investors own 16.85% of the company’s stock.

About Aravive

(Get Rating)

Aravive, Inc operates as a clinical stage biotechnology company. The firm engages in the development of new therapies that target important survival pathways for both advanced solid tumors as well as hematologic malignancies. Its product candidate, Aravive-S6, is a soluble Fc-fusion protein designed to block the activation of the GAS6-AXL signaling pathway by intercepting the binding of GAS6 to its receptor AXL which also promotes metastasis, cancer cell survival, resistance to treatments and immune suppression.